I'll research HSIC (Henry Schein) before writing the preview. Let me gather recent earnings, filings, and news.Let me read the most recent quarter (2026Q1) call and release, plus the recent leadership transition news.Let me get the Q1 2026 earnings release details and recent stock price action.Let me check recent news context (KKR/activist background and any analyst commentary) before writing.Let me pull the Q2 2025 release for the year-ago comparison base.# Henry Schein (HSIC) — Q2 2026 Earnings Preview
This is the second earnings print of the Fred Lowery era, and the story going in is almost entirely about self-help: gross-margin expansion, the >$200M value-creation program, and a just-announced management reorganization — all set against an easy year-ago comparison and a stock sitting near 52-week highs. The market has already voted with its feet: HSIC has rallied from ~$73 in early April to ~$86.5 on Aug 3, roughly +18%, so expectations have firmed up considerably heading into the print.
Q2 2025 was one of the company's weaker quarters. Under prior CEO Stan Bergman, HSIC posted: - Net sales $3.24B (+3.3% reported, +1.9% internal) - Non-GAAP EPS $1.10 (down 10.6% YoY) - Adjusted EBITDA $256M (down from $268M)
That weakness was self-inflicted/transitory: management cited lower glove pricing and "time-limited targeted sales initiatives" (aggressive promotions) that compressed U.S. distribution margins, plus a tariff-driven pause in U.S. equipment orders that started in May 2025. U.S. dental was actually down year-over-year in Q2 2025 (merchandise −1.2%, equipment −4.7%).
Implication: HSIC laps a depressed base with normalized promotional activity and improving margins. The bar to show YoY EPS and margin growth is low, so the more relevant question is whether results/guidance clear the now-higher buy-side bar embedded in the stock's run.
The Q1 print (reported May 5) set a constructive tone and is the best read on trajectory: - Sales $3.37B, +6.3% (internal +2.5%, FX +3.1%, M&A +0.7%) - Non-GAAP EPS $1.32, +14.8%; Adjusted EBITDA $289M, +11.6% - Gross margin +~25 bps YoY and +~86 bps vs Q4, driven by owned-brand mix, more dynamic value pricing, and early value-creation benefits - Non-GAAP operating margin 7.53%, +28 bps - U.S. dental internal growth +4.1% merchandise / +3.4% equipment — with management claiming market-share gains, aided by DSOs outgrowing the market - Global Technology internal growth +6.9%; Dentrix Ascend + Dentally cloud subscribers >13,000 (+~25% YoY) - Management noted March > February and April strong — i.e., positive exit velocity into Q2
Full-year 2026 guidance was reaffirmed: sales +3–5%, non-GAAP EPS $5.23–$5.37, Adjusted EBITDA mid-single-digit growth off a 2025 base of ~$1.1B, ~24% tax rate.
Just four business days before earnings, HSIC announced it is replacing its Executive Management Committee with a new "Henry Schein Leadership Team," integrating the global supply-chain org into global distribution, and moving three long-tenured executives — COO Michael Ettinger, Chief Strategy Officer Mark Mlotek, and SVP Global Supply Chain Jim Mullins — into senior advisory roles effective Oct 31, 2026.
Lowery framed this as making the company "simpler… prioritize and make decisions faster… more customer-centric." This is consistent with his stated agenda of building a "leaner, more agile Henry Schein" and a stronger performance culture. Expect this to be a major Q&A topic: investors will want to know whether it (a) is incremental to the $200M value-creation target or part of it, (b) carries additional restructuring charges, and (c) signals a faster/deeper cost takeout under KKR's influence.
1. Margins / value creation cadence. This is the crux of the bull case. Management guided savings to be second-half weighted, targeting a $125M run-rate by year-end 2026 en route to >$200M annually. Q2 should show early acceleration vs the "nominal" Q1 G&A benefit. Watch gross margin (owned-brand penetration, value pricing) and whether the $125M run-rate is reaffirmed or nudged.
2. Guidance action. With a strong H1 and back-half-weighted savings, the debate is reaffirm vs. raise. Given how much the stock has moved, a simple reaffirmation may be viewed as insufficient; a raise (or narrowing to the high end) would validate the rally. Note guidance assumes stable end markets, current FX, and that tariffs + higher oil can be mitigated.
3. Oil / freight sensitivity. A recurring theme — higher oil hits both freight costs and oil-based product pricing (e.g., gloves). Management said it can mitigate but acknowledged a "tipping point." Any commentary on surcharges/pricing actions and the assumed oil level matters.
4. Medical. Q1 medical internal growth was only +1.2%, dragged by a light flu season hitting point-of-care respiratory diagnostics (~15–20% of medical); ex-that, growth was mid-single digits, with Home Solutions and dialysis strong. Q2 is seasonally light for flu anyway, so watch the underlying medical trend and any ACA/Medicaid commentary.
5. Specialty / implants. Specialty internal growth was soft at +1.7% in Q1, with value implants high-single-digit but premium implants flat-to-down (worse in the U.S.). Management promised reacceleration through the year — Q2 is the first checkpoint. Watch premium implant recovery and the value/premium mix drag on gross margin.
6. Digital equipment. Intraoral scanner/3D printer ASPs pressured by new entrants even as volumes rise; management spins this as a razor/razor-blade funnel into future digital purchases. Traditional equipment backlog was called healthy — a positive DSO capex signal.
7. E-commerce milestone. henryschein.com was slated to complete U.S. rollout by end of August (>80% of U.S. dental e-commerce already on it), then extend internationally — a potential efficiency/share-of-wallet catalyst.
8. EPS quality / buybacks & remeasurement gains. - Buybacks are a real EPS tailwind: diluted share count fell to ~116M in Q1 from ~125M a year ago (~7% reduction), with $655M remaining on the authorization ($125M repurchased in Q1). - Remeasurement gains from buying out JV minority partners (e.g., the $11M / ~$0.07 S.I.N. gain in Q1) flow into results; management guided 2026 gains below 2025 with any further gains in H2. Scrutinize how much of any EPS beat is operational vs. these one-timers.
HSIC enters the print with momentum, an easy comp, and a credible self-help story, but also with a stock near highs and expectations reset upward. The likely swing factors are: (1) magnitude and durability of gross-margin expansion, (2) whether the value-creation savings visibly accelerate into the second half, (3) any guidance raise, and (4) how the fresh management reorg is framed (incremental savings vs. reshuffle, and any new restructuring charges). Watch the quality of any EPS beat given the buyback and JV-remeasurement tailwinds, and management's tone on oil/freight, medical normalization, and specialty reacceleration.
Note: HSIC guides on a non-GAAP basis only and does not provide GAAP guidance (owing to unpredictable restructuring charges), so focus comparisons on non-GAAP EPS and Adjusted EBITDA.